Show
Sort by
-
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria
-
Health economic consequences of irbesartan treatment of type 2 diabetes patients with nephropathy and hypertension in Germany
-
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting
-
Cost-efectiveness of irbesartan in type II diabetic nephropathy with hypertension. A spanish perspective
-
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease
-
An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings
-
Irbestartan is projected to be cost and life saving in the USA for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria